<DOC>
	<DOCNO>NCT00001357</DOCNO>
	<brief_summary>This Phase I dose-escalating safety study aim identify maximum tolerate dose ( MTD ) outpatient regimen expose minimum number patient dose less MTD . The anticipated accrual approximately 15 patient study take one year complete . Patients receive Proleukin速 ( Registered Trademark ) subcutaneously assign dose level per day 5 day approximately every eight week total 6 month . A cycle therapy define 5 day Proleukin速 ( Registered Trademark ) plus antiviral therapy follow 7 week antiviral therapy alone . If tolerate , patient receive 3 cycle therapy , follow completion three cycle , eligible extend treatment . IL-2 injection deliver study personnel outpatient basis least first cycle therapy .</brief_summary>
	<brief_title>Subcutaneously Administered Interleukin-2 Therapy HIV-Infected Patients</brief_title>
	<detailed_description>This Phase I dose-escalating safety study aim identify maximum tolerate dose ( MTD ) outpatient regimen expose minimum number patient dose less MTD . The anticipated accrual approximately 15 patient study take one year complete . Patients receive Proleukin速 ( Registered Trademark ) subcutaneously assign dose level per day 5 day approximately every eight week total 6 month . A cycle therapy define 5 day Proleukin速 ( Registered Trademark ) plus antiviral therapy follow 7 week antiviral therapy alone . If tolerate , patient receive 3 cycle therapy , follow completion three cycle , eligible extend treatment . IL-2 injection deliver study personnel outpatient basis least first cycle therapy .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>18 year age older positive HIV1 ELISA Western blot . CD4+ cell count great equal 350 cells/mm ( 3 ) . No prior IL2 therapy . No antiretroviral therapy 6 week prior study entry . Willingness remain antiretrovirals 12 month protocol define recommendation require change determine . No therapy systemic corticosteroid , chemotherapy , experimental therapy 4 week prior entry study . SGOT le equal 150 microliter/l ; Hgb great 10 gm/dl ; Granulocyte count less equal 1,000/mm ( 3 ) ; T. bilirubin less equal 2.0 mg/dl ; Serum creatinine less equal 2.0 mg/dl ; Proteinuria le equal 1+ ; platelet count great 75,000 . No history AIDSdefining opportunistic infection , malignancy mucocutaneous Kaposi sarcoma . No significant cardiac , pulmonary , kidney , rheumatologic , gastrointestinal , psychiatric , neurological disease . No pregnancy breastfeed . No avascular necrosis bone . Patient must fully inform know benefit antiretroviral therapy . HOME PATIENTS : Patient must enrol good stand current NIAID protocol involve use IL2 therapy . The patient must already undergo least one year treatment protocol IL2 therapy give , include least 2 welltolerated outpatient cycle scIL2 stable dose . The patient must history generally tolerable side effect receive IL2 require frequent medical intervention , intravenous fluid replacement , and/or IL2 dose reduction . Conditions generally suitable home scIL2 administration would include ( limited ) unusually heavy requirement narcotic usage cycle , significant urticaria ( hive ) allergic condition , history possible airway compromise due throat swell . Patient must experience serious ( grade 3 high ) clinical laboratory abnormality medical significance day 05 last 2 outpatient scIL2 cycle . The patient must strong relationship private physician healthcare provider home demonstrate close involvement patient 's care date would willing help supervise patient 's care home scIL2 cycle . Because need identify single healthcare provider home agree available render care ( need ) patient 's scIL2 cycle , patient currently receive home care rotate staff member general clinic setting may eligible home scIL2 administration . A signed write statement acknowledge willingness participate monitoring must receive clinic 8 study team private physician healthcare provider prior first home scIL2 cycle . In addition , communication must occur clinic 8study team designate physician healthcare provider prior subsequent cycle confirm individual 's continued willingness serve onsite provider serious medical condition might develop cycle . The patient must live home address easy access telephone must demonstrate reliability respond telephone call clinic 8 staff member . The patient must also able provide study team reliable contact information close family member friend agree serve capacity `` caregiver '' cycle : i.e. , someone able render nonmedical assistance patient able check condition daily event emergency medical assistance need summon . It become patient 's responsibility ensure local `` caregiver '' communicate willingness serve capacity telephone clinic 8study team prior cycle . The patient must `` reasonable '' ( i.e. , rapid close ) access home emergency medical service nearby medical facility event medical crisis . The suitability athome situation assess casebycase basis clinic 8study team . The patient must demonstrate reliability consistency sterile technique , reconstitution IL2 vial , preparation administration scIL2 injection . The patient must receive outpatient scIL2 cycle least every 6 month part normal protocol participation , except discretion study team . The patient must access reliable home weight scale able weigh accurately daily basis purpose safety monitoring .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2002</verification_date>
	<keyword>Cytokines</keyword>
	<keyword>Immunoregulation</keyword>
	<keyword>CD4 Cells</keyword>
</DOC>